{
    "nct_id": "NCT06582875",
    "official_title": "Advancing ADPKD Treatment With GLP-1RA: A Study of Glucagon-Like Peptide-1 Receptor Agonists' Efficacy, Safety, and Mechanism",
    "inclusion_criteria": "* 18-65 years of age\n* ADPKD diagnosis based on the modified Pei-Ravine criteria\n* Body-mass index of ≥27 kg/m^2\n* Estimated glomerular filtration rate ≥ 30 mL/min/1.73m^2\n* Mayo Classification of C, D, or E, calculated from a previous kidney ultrasound or MRI performed within the last 12 months\n* Not currently participating in or planning to participate in any formal weight loss or physical activity program, or another interventional study\n* Ability to provide informed consent\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 65 Years",
    "exclusion_criteria": "* Diabetes mellitus\n* Tolvaptan usage or plans to initiate tolvaptan\n* History of hospitalization or major surgery within the last 3 months\n* Uncontrolled hypertension (systolic blood pressure > 160 or diastolic blood pressure >100 mm Hg)\n* Pregnancy, lactation, or unwillingness to use adequate birth control\n* Regular use of prescription or over-the-counter medications that may affect weight, appetite, food intake, or energy metabolism\n* History of clinically diagnosed eating disorder including: anorexia nervosa, bulimia, binge eating disorder\n* Weight change of >5% in the past 3 months for any reason except post-partum weight loss\n* Inability to cooperate with or clinical contraindication for MRI including: severe claustrophobia, implants, devices, or non-removable body piercings\n* Presence or personal history of malignant neoplasm within 5 years prior to the day of screening\n* Personal or family history of medullary thyroid carcinoma, thyroid nodule, or multiple endocrine neoplasia type 2\n* Prior history of pancreatitis\n* Weight ≥450 lb",
    "miscellaneous_criteria": ""
}